Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials

<p>The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following a two-dose schedule of ChAdOx1 nCoV-19/AZD1222, in the absence of infection, and also e...

Full description

Bibliographic Details
Main Authors:	Voysey, M, Flaxman, A, Aboagye, J, Aley, PK, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Charlton, S, Clutterbuck, EA, Davies, S, Dold, C, Edwards, NJ, Ewer, K, Faust, SN, Folegatti, PM, Fowler, J, Gilbride, C, Gilbert, SC, Godfrey, L, Hallis, B, Humphries, HE, Jenkin, D, Kerridge, S, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Snape, MD, Song, R, Thomas, KM, Ulaszewska, M, Woods, D, Wright, D, Pollard, AJ, Lambe, T
Format:	Journal article
Language:	English
Published:	Oxford University Press 2023

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials

Similar Items